DCP
VERA icon

Davern Capital Partners’s Vera Therapeutics VERA Stock Holding History

Davern Capital Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
+498,832
New +$18.6M 3.65% 12

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Davern Capital Partners's VERA Position: Q2 2026 in Review

Davern Capital Partners opened a new position in Vera Therapeutics (VERA) in Q2 2026: 498,832 shares worth $21.4M. The stake represents 3.65% of the portfolio and ranks #12 among its holdings.

219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Davern Capital Partners held 498,832 shares of Vera Therapeutics worth $21.4M as of Q2 2026.
  • Vera Therapeutics was a new Davern Capital Partners position in Q2 2026.
  • Vera Therapeutics made up 3.65% of Davern Capital Partners's portfolio in Q2 2026, its #12 holding.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.